Colorectal cancer liver metastases: mechanism and therapy
-
By
-
Shan Liu
-
Liuxian Ban
-
Wei Zhang
-
Yutian Sun
-
Ke Wang
-
Yuxin Man
-
Yinjie Zhang
-
July 10, 2026
-
Clinical Scorecard: Mechanisms and Treatment Approaches for Liver Metastases in Colorectal Cancer
At a Glance
| Category | Detail |
|---|
| Condition | Colorectal cancer liver metastases (CRLM) |
| Key Mechanisms | Immune evasion, metastatic colonization, and therapeutic resistance driven by the liver's immune-tolerant microenvironment. |
| Target Population | Patients with colorectal cancer, particularly those with liver metastases. |
| Care Setting | Oncology and specialized cancer treatment centers. |
Key Highlights
- CRLM accounts for approximately 70% of deaths in colorectal cancer patients.
- The liver's unique immune environment facilitates tumor cell colonization and immune evasion.
- Current treatments include chemotherapy, radiotherapy, targeted therapy, and immunotherapy.
- Survival rates for CRLM patients remain below 40%.
- Emerging treatment strategies focus on understanding the hepatic immune microenvironment.
Guideline-Based Recommendations
Diagnosis
- Assess for liver metastases in patients diagnosed with colorectal cancer.
Management
- Utilize a combination of chemotherapy, targeted therapy, and immunotherapy based on individual patient profiles.
Monitoring & Follow-up
- Regular imaging and clinical evaluations to monitor disease progression and treatment response.
Risks
- High risk of liver-specific recurrence in patients with a history of liver metastases.
Patient & Prescribing Data
Patients with colorectal cancer and confirmed liver metastases.
Combination therapies may enhance treatment efficacy by targeting the unique mechanisms of CRLM.
Clinical Best Practices
- Consider the immunosuppressive microenvironment when designing treatment strategies.
- Monitor for signs of therapeutic resistance in patients receiving treatment for CRLM.
Related Resources & Content
